https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Improving the delivery of primary care for older people https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41487 Wed 24 Aug 2022 15:37:00 AEST ]]> Patients with skin disease and their relationships with their doctors: a qualitative study of patients with acne, psoriasis and eczema https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6982 Sat 24 Mar 2018 08:37:51 AEDT ]]> How generalisable are results of studies conducted in practice-based research networks?: a cross-sectional study of general practitioner demographics in two New South Wales networks https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14496 Sat 24 Mar 2018 08:21:40 AEDT ]]> Correlation and agreement of self-assessed and objective skin disease severity in a cross-sectional study of patients with acne, psoriasis, and atopic eczema https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17418 Sat 24 Mar 2018 08:01:38 AEDT ]]> An evaluation of the additional benefit of population screening for dementia beyond a passive case-finding approach https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30671 95% in both groups. GPs and their patients both found the GPCOG to be an acceptable cognitive assessment tool. The dementia cases missed via case-finding were younger (p = 0.024) and less cognitively impaired (p = 0.020) than those detected. Conclusion: There is a very limited benefit of screening for dementia, as most people with dementia could be detected using a case-finding approach, and considerable potential for social and economic harm because of the low PPV associated with screening.]]> Sat 24 Mar 2018 07:29:36 AEDT ]]> Screening for dementia in primary care: a comparison of the GPCOG and the MMSE https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26028 Sat 24 Mar 2018 07:26:29 AEDT ]]> Anticholinergic burden in older women: not seeing the wood for the trees? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25011 Sat 24 Mar 2018 07:10:40 AEDT ]]> Stability of anticholinergic load in Australian community-dwelling older people: a longitudinal analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40610 n = 1768), at year one (n = 1373) and a restricted cohort (with possible or definite cognitive impairment) at year two (n = 370) had medication regimens documented by a research nurse during a home visit. Anticholinergic medicines were categorized as levels 1-3 (low-high potency) and summed for each participant as a measure of their ACL. RESULTS: Most participants had no change in ACL over time, but there was some turnover in the anticholinergic medications used. The mean change in ACL was 0.012 ± 0.99 from baseline to 12 months and −0.04 ± 1.3 from baseline to 24 months. Cardiovascular drugs were the most commonly used level 1 anticholinergics, followed by antidepressants and opioids. Antidepressants and urologicals were the most commonly used level 3 anticholinergics. The rate of anticholinergic deprescribing was equivalent to the rate of anticholinergic initiation, and commonly involved the level 1 drugs warfarin, furosemide and temazepam, and the level 3 drugs amitriptyline and oxybutynin. People with dementia had a higher ACL at baseline and year one compared with other participants. CONCLUSION: ACL of community-dwelling older people was very stable over time. This may represent lost opportunities for deprescribing as well as potentially inappropriate prescribing, particularly in those with cognitive impairment.]]> Fri 15 Jul 2022 11:49:13 AEST ]]>